Navigation Links
Hepatitis C Virus Market Will Expand Dramatically From $2 Billion in 2008 to Nearly $7.7 Billion in 2013
Date:6/22/2009

Roche and Schering-Plough Will Continue to be Prominent Players in the Market, According to a New Report from Decision Resources

WALTHAM, Mass., June 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the hepatitis C virus drug market will expand dramatically from $2 billion in 2008 to nearly $7.7 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, market growth thereafter will decrease to $3.4 billion in 2018 owing to a decline in the prevalence of the disease and the high efficacy of new treatment regimens.

The new Pharmacor report entitled Hepatitis C Virus finds that, through 2013, robust market growth will be driven by the launches of novel hepatitis C virus-specific agents and an increase in the size of the drug-treated population. Roche and Schering-Plough will continue to be prominent players and a number of other companies -- including Johnson & Johnson and Pfizer -- will also carve out a share in the market.

The report also finds that the competitive hepatitis C virus pipeline is characterized by its significant commercial potential which is well-recognized by drug developers. Several agents in late-stage development -- most notably protease inhibitors such as Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir and Schering-Plough's boceprevir as well as polymerase inhibitors such as Roche/Pharmasset's R-7128 and Pfizer's filibuvir -- will drive market growth.

"The standard of care will change significantly with the introduction of new classes of hepatitis C virus-specific antiviral agents, such as protease inhibitors and polymerase inhibitors," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "Compounds from these new classes will initially be added to the backbone of currently used agents, forming triple or quadruple treatment regimens that are expected to be more efficacious than the current standard of care."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                               Decision Resources, Inc.
    Christopher Comfort                              Elizabeth Marshall
    781-296-2597                                     781-296-2563
    ccomfort@dresources.com                          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Good news for some hard-to-treat hepatitis C patients
2. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
3. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
4. NEJM study points to new era in hepatitis C treatment
5. Resource for Those Living with Hepatitis C Announces Website Redesign
6. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
7. New treatment option for patients with chronic hepatitis C
8. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
9. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
10. World Health Assembly Forced to Postpone Decision on Viral Hepatitis
11. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... Texas (PRWEB) , ... April 21, 2017 , ... The ... Secours Baltimore Health System, with the 2017 Ruth Ravich Patient Advocacy Award ... fellow patient advocates. DeVaro was honored with the award at The Beryl Institute’s annual ...
(Date:4/21/2017)... ... 2017 , ... The Hong Kong Polytechnic University (PolyU) launched today the University ... institutions in Hong Kong to support teaching, learning and research. It is also the ... facilities in Hong Kong. , With an area of 620 square metres and ...
(Date:4/21/2017)... ... 2017 , ... The American Medical Student Association (AMSA) will ... Education, from April 24 to April 28, 2017, dedicated to increasing awareness about ... mission of AWARE is to instill a compassionate, total health approach to treating ...
(Date:4/21/2017)... ... 2017 , ... Airway Management, the medical device manufacturer of ... and well renowned Asian distributor, Discovery Sleep. The agreement involves the ... and will stabilize and strengthen Airway’s presence with a dedicated, reputable medical device ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... -- The Mobile X-Ray product segment is the most attractive ... forecast period Mobile X-Ray segment is the largest ... devices market, which is estimated to be valued at more ... of 7% over the forecast period. Mobile X-Ray segment is ... 100 Mn in 2017 over 2016. The segment,s revenue in ...
Breaking Medicine Technology: